On May 31, 2026 Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, reported the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data from the ongoing Phase 1 study of IMA401 will be presented on May 31, 2026, during the Developmental Therapeutics Session – Immunotherapy from 8:00-11:00 am CDT by Martin Wermke, M.D., TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany (Abstract ID: 2507). The slides are available in the ‘Events & Presentations’ section of the Investor & Media page on the Company’s website.

Carsten Reinhardt, M.D., Ph.D., Chief Development Officer at Immatics, said, "The IMA401 clinical data represent an important step forward for our next-generation, off-the-shelf TCER platform and reinforce the potential of this modality to address both advanced and earlier-stage solid tumors. Building on the encouraging clinical activity and supportive preclinical findings, we believe IMA401 may have even greater potential in combination with IMA402, our PRAME-directed bispecific. The initiation of the IMA401/IMA402 combination cohort in squamous cell non-small cell lung cancer marks a milestone toward broadening patient reach and delivering meaningful clinical benefit for patients with significant unmet needs."

Based on the clinical data for IMA401, including the initial clinical signal in squamous cell non-small cell lung cancer (sqNSCLC), as well as preclinical proof-of-concept data and clinical data for IMA402, Immatics has initiated enrollment in a Phase 1 cohort at multiple clinical trial sites evaluating IMA401 targeting MAGEA4/8 in combination with IMA402 targeting PRAME in sqNSCLC. The dual targeting approach is designed to broaden patient coverage and potentially enhance anti-tumor activity by addressing two highly prevalent cancer targets, with sqNSCLC as the first indication, and further development potential for many others. Based on combined target prevalence, more than 90% of patients with sqNSCLC express PRAME and/or MAGEA4/8. The current addressable patient population for metastatic sqNSCLC in the United States and EU5 is estimated at approximately 40,000 patients per year. First data from the IMA401/IMA402 combination cohort are expected in 2027.

Highlights of Immatics’ clinical data on IMA401

Patient population: Heavily pretreated, highly heterogeneous patient population

As of the data cutoff on March 2, 2026, 61 patients with recurrent and/or refractory solid tumors across >15 different tumor types were treated with IMA401 with or without an immune checkpoint inhibitor (ICI, pembrolizumab) in a Phase 1 dose-escalation basket trial (NCT05359445).
Patients were heavily pretreated with a median of three prior lines of systemic treatment (range: 1-8).
44 patients were treated at RP2D (1-2 mg), with 32 receiving monotherapy and 12 receiving the combination of IMA401 and pembrolizumab. Among these patients, head and neck cancer represented the largest subgroup treated at RP2D (n=14).

Safety: Favorable tolerability at RP2D supporting broad combinability of IMA401

The tolerability profile of IMA401 with or without pembrolizumab was consistent across patient populations.
The most frequent clinically relevant treatment-related adverse events (TRAE) observed across dose levels were low-grade cytokine release syndrome (CRS) (38% G1-2, no ≥ Grade 3), expected and transient lymphopenia (33%), consistent with the mechanism of action, and neutropenia (31%). Within the RP2D range of 1-2 mg, neutropenia was mostly transient and manageable.
Notably, no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.
Tolerability of IMA401 at RP2D in combination with pembrolizumab was consistent with IMA401 as a monotherapy at RP2D, with no overlapping and/or additive toxicity observed.
Tolerability profile of IMA401, both as a monotherapy and with pembrolizumab, supports broad combination potential of IMA401.

Anti-tumor activity and durability: Promising clinical activity with deep and durable responses
Patients treated with IMA401 at RP2D as a monotherapy or in combination with pembrolizumab demonstrated clinical activity across multiple solid tumor indications, including melanoma, sqNSCLC, head and neck cancer and others:

Head and neck cancer (largest patient subgroup treated at RP2D): confirmed objective response rate (cORR) of 29% (4/14), disease control rate (DCR) of 64% (9/14), median duration of response (mDOR) of 8.8 months. The 12-month overall survival (OS) rate was 63% and the six-month progression-free survival (PFS) rate was 43%. All responders achieved deep tumor reduction ranging from 60-100% and three of four responders were ongoing at data cutoff.
Melanoma: cORR of 33% (2/6), DCR of 67% (4/6); both confirmed responses lasted beyond six months post treatment, with one ongoing for >2.5 years.
sqNSCLC: A presented patient case highlighted a patient with ICI-resistant sqNSCLC who received IMA401 plus pembrolizumab in fifth-line (prior best overall response: stable disease) and achieved a partial response with shrinkage of all target lesions.

Preclinical data: Supporting broad patient coverage and potential synergistic activity of IMA401/IMA402 combination

Target expression data from analyzed tumor samples showed that >90% of patients with sqNSCLC are positive for PRAME and/or MAGEA4/8, and ~60% of patients with sqNSCLC are positive for both targets, suggesting that a combination therapy against both targets could boost anti-tumor activity and counteract potential tumor escape mechanisms.
IMA401/IMA402 combination demonstrated synergistic anti-tumor activity in MAGEA4/8 and PRAME double-positive tumor cell lines.
Data on the IMA401 Phase 1 trial are published simultaneously in Nature Medicine.

About Immatics TCR Bispecifics (TCER)
Immatics’ next-generation half-life extended TCER molecules are antibody-like "off-the-shelf" biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. The design of the TCER molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells’ intrinsic specificity. Immatics’ proprietary biologics are engineered with two binding regions: a TCR domain and a T cell recruiter domain. The TCER format is designed to maximize efficacy while minimizing toxicities in patients. It contains a high-affinity TCR domain that is designed to bind specifically to the cancer target peptide on the cell surface presented by an HLA molecule. The antibody-derived, low-affinity T cell recruiter domain is directed against the TCR/CD3 complex and recruits a patient’s T cells to the tumor to attack cancer cells. With a low-affinity recruiter aiming for optimized biodistribution and enrichment of the molecule at the tumor site instead of the periphery, TCER are engineered to reduce the occurrence of immune-related adverse events, such as cytokine release syndrome. In addition, the TCER format comprises an Fc part that confers half-life extension, stability, and manufacturability. TCER molecules are "off-the-shelf" biologics and thus immediately available for patient treatment. They can be distributed through standard pharmaceutical supply chains and can reach a large patient population without the need for specialized medical centers.

About IMA401 MAGEA4/8 Bispecific
IMA401 is a molecule from Immatics’ TCR bispecifics pipeline that targets an HLA-A*02:01-presented peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 ("MAGEA4/8"). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT and is presented at a 5-fold higher target density (copy number per tumor cell) than the MAGEA4 peptide targeted in other clinical trials. IMA401 is currently being evaluated in a Phase 1 basket trial in patients with MAGEA4/8-positive solid tumors. The MAGEA4/8 peptide has a high prevalence in several solid tumor indications such as head and neck squamous cell carcinoma (HNSCC), squamous cell non-small cell lung cancer (sqNSCLC), as well as melanoma and other solid cancer types.

About IMA402 PRAME Bispecific
IMA402 is a molecule from Immatics’ TCR bispecifics (TCER) pipeline directed against an HLA-A*02:01-presented peptide derived from PRAME. IMA402 is currently being evaluated in a Phase 1 trial in patients with solid tumors expressing PRAME. IMA402 is part of Immatics’ strategy to leverage the full clinical potential of targeting PRAME, one of the most promising targets for TCR-based therapies.

(Press release, Immatics, MAY 31, 2026, View Source [SID1234666247])

On May 31, 2026 Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, reported updated data from the Phase 1 PoC clinical study of its first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the treatment of advanced immunotherapy(IO)-resistant non-small cell lung cancer (NSCLC) The detailed data was presented today at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The updated data is from a PoC clinical study conducted in China to evaluate the safety and efficacy of IBI363 monotherapy in subjects with advanced NSCLC (ClinicalTrials.gov, NCT05460767). As of the follow-up cutoff date of November 20, 2025, a total of 136 subjects with NSCLC had received IBI363 monotherapy (2 μg/kg QW~4mg/kg once every 3 weeks, Q3W).

IBI363 Showed Robust Survival Benefits with a Long Tail Effect in IO-Resistant Squamous NSCLC

All 67 squamous NSCLC patients had no known EGFR mutations. Among them, 28 patients received IBI363 at 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 31 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg Q3W dose group, the median PFS reached 10.1 (95%CI 6.0, 14.0) months, and the median OS achieved 18.2 (95%CI 10.7, NE; maturity 48.4%) months, with a 24-month OS rate of 47.8% (95%CI 28.7, 64.7).
IBI363 Showed Potential for Long-Term Survival Benefits with a Long Tail Effect in IO-Resistant Wild-type AdenoNSCLC, Especially in Patients with a Smoking History

Among the 58 patients with EGFR wild-type adenoNSCLC, 30 patients received IBI363 at 0.6 mg/kg Q2W or 1 mg/kg Q2W or 1.5 mg/kg Q3W, and 25 patients received IBI363 at 3 mg/kg Q3W. In the 3 mg/kg dose group, the median PFS reached 4.2 (95%CI 3.0, 7.0) months, and the median OS achieved 15.2 months (95%CI 9.6, NE; maturity 56.0%), with a 24-month OS rate of 42.7% (95%CI 23.1, 61.0).
Smoking history may be an important influencing factor for efficacy in immuno-resistant adenoNSCLC. In adenoNSCLC subjects with a smoking history, better survival benefits were observed. The median OS for smokers across all dose groups (N=31) reached 23.4 (95%CI 11.3, NE, maturity 48.4%) months.
IBI363 Showed a Favorable Safety Profile in Long-Term Follow-up

In the long-term follow-up of the overall population (n = 136), IBI363 demonstrated a favorable safety profile: treatment-emergent adverse events (TEAEs) of grade 3 or above occurred in 30.6% of patients treated with 1/1.5 mg/kg and 64.9% of patients treated with 3mg/kg.
The most common adverse events among all patients were arthralgia (52.2%, 3.7% ≥grade 3), anemia (46.3%, 4.4% ≥grade 3), and rash (39.0%, 8.8% ≥grade 3), which were mostly controllable and manageable with mild-to-moderate AEs. No new safety signals were observed.
Professor Jianya Zhou, The First Affiliated Hospital, School of Medicine, Zhejiang University, commented: "Lung cancer remains the most commonly diagnosed and deadliest malignancy worldwide, representing a major public health challenge. Despite the transformative impact of immunotherapy on the treatment landscape of NSCLC, patients with wild-type NSCLC who experience disease progression following immunotherapy continue to face limited treatment options, with docetaxel-based standard-of-care therapy offering only modest efficacy.

In recent years, emerging approaches such as immunotherapy-based combinations and ADCs have brought new hope. However, multiple large-scale Phase III clinical trials in NSCLC patients who had failed both platinum-based chemotherapy and immunotherapy have not yet delivered satisfactory outcomes. Therefore, there remains a substantial and urgent unmet medical need in the post-immunotherapy setting for NSCLC.

As a PD-1/IL-2α-bias bispecific molecule, IBI363 has demonstrated encouraging clinical benefit in immunotherapy-resistant NSCLC, with both objective response rate (ORR) and progression-free survival (PFS) showing meaningful improvement. Notably, in the 3 mg/kg Q3W cohort, more than 40% of patients with either squamous or adenocarcinoma histology survived beyond 24 months. These findings highlight the potential of IBI363 to generate a durable immunotherapy tail effect and deliver long-term survival benefits for patients."

Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent, stated: "While immunotherapy has significantly improved survival outcomes for certain patients, treatment options remain extremely limited for patients with NSCLC who do not respond to immunotherapy and lack actionable driver gene mutations, making long-term survival difficult to achieve.The proof-of-concept (PoC) data presented at this year’s ASCO (Free ASCO Whitepaper) meeting are highly encouraging. IBI363 has demonstrated not only meaningful short-term disease control, but also, through extended follow-up, validated the unique long-term survival benefits of its dual mechanism of action, combining immune checkpoint blockade with cytokine agonism. We are excited about the potential of IBI363 to provide a novel treatment option for a broad population of patients and ultimately help deliver durable, long-term survival benefits."

About IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein)

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific fusion protein developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and selectively activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2 to the tumor through binding to IL-2 receptor alpha.

IBI363 is being evaluated in a series of clinical trials globally, led by a pivotal Phase II study in China in previously untreated acral and mucosal melanoma and a global multi-regional Phase III trial in immunotherapy-resistant squamous NSCLC. In parallel, multiple Phase Ib/II trials are evaluating IBI363 in NSCLC and CRC including the first-line and later line settings, and in additional tumor types. IBI363 has received two Fast Track Designations (FTD) from the U.S. FDA and three Breakthrough Therapy Designations (BTD) from China NMPA so far.

In October 2025, Innovent entered into a license and collaboration agreement with Takeda, under which Innovent and Takeda will co-develop IBI363 (Takeda R&D code: TAK-928) globally and co-commercialize IBI363 in the U.S., and Takeda will exclusively commercialize IBI363 worldwide other than the U.S. and greater China.

(Press release, Innovent Biologics, MAY 31, 2026, View Source;innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1il-2-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunotherapy-resistant-non-small-cell-lung-302786450.html [SID1234666265])

On May 31, 2026 Immunocore Holdings plc (Nasdaq: IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, reported updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. The data is presented in a poster at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am pleased to present these updated brenetafusp data at ASCO (Free ASCO Whitepaper). Patients with advanced melanoma who progress on anti-PD-1 therapy have limited options, and seeing meaningful disease control in heavily pretreated patients is genuinely promising. These results support continued evaluation of brenetafusp in advanced melanoma," said Professor Georgina Long, Medical Director, Melanoma Institute Australia, The University of Sydney.

"These data with brenetafusp in heavily pretreated advanced melanoma show consistent responses and survival even in those with poor prognosis, including patients with primary PD-1 resistance," said Mohammed Dar, Chief Medical Officer of Immunocore. "These data also reinforce our confidence in the potential of brenetafusp at the dose of 160 mcg in combination with nivolumab in first-line advanced melanoma, in the ongoing Phase 3 PRISM-MEL-301 trial."

Phase 1/2 efficacy data

In the 66 patients treated with brenetafusp monotherapy (target doses 20-320 mcg), the median overall survival (OS) was 14.3 months (95% CI: 11.3-20.4; median follow up of 22.4 months) with a landmark OS rate of 87% at 6 months and 57% at 12 months. The disease control rate (DCR = partial responses and stable diseases) was 52%, while the overall response rate (ORR) was 12%.

Multiple measures of clinical benefit (6-month OS, DCR, ORR, tumor reduction) were numerically higher for patients treated with the 160 mcg dose – despite worse baseline prognostic factors compared to those treated with 40 mcg. These data support selection of 160 mcg for the ongoing Phase 3 trial evaluating brenetafusp + nivolumab vs. standard nivolumab regimens (NCT06112314) in first-line advanced melanoma. The safety profile was similar at both doses.

Median OS was 14.7 months for patients with primary PD-1 resistance, defined as progression within 6 months of starting the first regimen containing anti-PD1. Despite these patients having primary PD-1 resistance, the median OS was similar to all monotherapy patients (14.3 months).

In exploratory analyses, circulating tumor DNA (ctDNA) response in patients with PD-1 primary resistance was numerically higher (53%; 8/15) compared to the overall group (38%; 19/50). Treatment outcome was not impacted by PD-L1 status and was shown, in this exploratory analysis, to be associated with tumor expression of beta 2 microglobulin – a protein involved in antigen presentation – and baseline peripheral blood T cell fitness, which has been shown to be better in earlier lines of therapy.

In the 10 patients treated with brenetafusp in combination with pembrolizumab, the data showed numerically higher ORR and DCR compared to monotherapy, with efficacy also reported in patients with PD-1 primary resistance.

Phase 1/2 safety data

Brenetafusp was generally well tolerated, showing a predictable, mechanism-driven safety profile as monotherapy and in combination. The most common treatment-related adverse events (TRAEs) (≥20%) – which were reversible and attenuated over time – included CRS (56%; predominantly low grade, reversible, and attenuated over time), rash (44%), pyrexia (44%), chills (38%), fatigue (31%), decreased lymphocyte count (38%), nausea (25%), and pruritus (44%). The most frequent Grade 3-4 TRAE was transient decreased lymphocyte count (25%). There were three TRAEs that led to treatment discontinuation (two monotherapy patients and one combination patient).

Phase 1/2 trial overview

The Phase 1/2 trial (NCT04262466; EudraCT 2019-004046-16) enrolled patients with unresectable or metastatic melanoma who were HLA-A*02:01-positive (central testing) and previously treated with anti-PD-(L)1 therapy. Brenetafusp was administered as a weekly IV infusion with step dosing to a target dose. Tumor response was assessed by RECIST every 9 weeks; ctDNA was assessed every three weeks.

Second poster: Effect of IL7 on T cell fitness and ImmTAC anti-tumor activity

In a second poster presented during ASCO (Free ASCO Whitepaper) 2026, the Company built on previously disclosed data regarding the importance of T cell fitness for the efficacy of ImmTAC molecules. The new data demonstrated the anti-tumor activity of these therapies may increase when combined with IL7 in vitro. This study showed that IL7 treatment expanded naïve/stem-like memory T cells, enhanced ImmTAC-mediated T cell induction of IFNγ secretion and tumor killing, as well as reduced immune checkpoint receptor expression and T cell exhaustion. Additionally, a single dose of IL7 resulted in a sustained increase in T cell fitness of cancer patients. Taken together, the in vitro and in vivo data are consistent with the hypothesis that a combination with IL7 may increase the anti-tumor activity of ImmTAC therapies.

Presentations details (ASCO 2026)

Title: Phase 1 evaluation of the PRAME-targeted ImmTAC brenetafusp in advanced melanoma (Mel). (Abstract number: 9527)
Session: Melanoma/Skin Cancers (Poster Board: 243)
Date and Time: May 31, 2026, 9:00 AM-12:00 PM CDT

Title: Effect of IL7 on ImmTAC-mediated killing by T cells in vitro and T cell fitness in patients (Abstract number: 2662)
Session: Developmental Therapeutics – Immunotherapy (Poster Board: 452)
Date and Time: May 30, 2026, 1:30 PM-4:30 PM CDT

(Press release, Immunocore, MAY 31, 2026, View Source [SID1234666248])

On May 31, 2026 ImmVira Group ("ImmVira") reported that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. As of the data cut-off on January 31, 2026, the optimized dose of MVR-T3011 achieved a 100% complete response rate (CRR) in BCG-unresponsive carcinoma in situ (CIS) and a durable 90% recurrence-free survival (RFS) in papillary (Ta/T1) tumors[1].

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

While intravesical instillation of Bacillus Calmette-Guérin (BCG) remains the standard of care for high-risk NMIBC-representing 75% of all newly diagnosed bladder cancer cases, a global BCG shortage and high rates of non-response leave a significant patient population without effective options. MVR-T3011 was developed with the goal of delivering potent local and systemic anti-tumor immunity directly within the bladder, offering a potential organ-preserving treatment option for this high-need population.

The ongoing trial enrolled 46 patients in total with pathologically confirmed BCG-unresponsive high-risk NMIBC. Patients received intravesical MVR-T3011 at one of two dose levels:

Lower-dose group (2×109 PFU): Induction course followed by maintenance dosing over two years (n=25).
Higher-dose group (1×1010 PFU): Induction course followed by maintenance dosing over two years (n=21).
The results demonstrate that MVR-T3011 achieved meaningful clinical efficacy and a favorable safety profile across both carcinoma in situ (CIS) and papillary (Ta/T1) disease settings：

In the CIS cohort, the higher-dose 1×1010 PFU regimen achieved a 100% complete response rate (CRR) at 3 months, 6 months, and 9 months, as well as at any assessed timepoint— a marked step up from the lower-dose 2×109 PFU cohort, which achieved a 66.7% CR rate at any timepoint (with timepoint-specific CRRs of 55.6% at 3 months and 75.0% at 6 months). The 12-month CRR for the 1×1010 PFU cohort has not yet been reached, with follow-up ongoing.
In the papillary (Ta/T1) cohort, the 2×109 PFU dose delivered a durable 12-month recurrence-free survival (RFS) of 74.0%, an already strong outcome; at the higher 1×1010 PFU dose, 9-month RFS reached 90.0%, with longer-duration follow-up ongoing.
Across all 46 patients treated, MVR-T3011 demonstrated a manageable safety profile consistent with prior observations. Importantly, the higher-dose 1×1010 PFU cohort showed a safety profile consistent with the lower-dose 2×109 PFU cohort, with no Grade 4 or 5 TEAEs reported across either dose level, or no deaths attributable to treatment.

"The presentation of these Phase IIa results at ASCO (Free ASCO Whitepaper) 2026 marks a meaningful milestone for ImmVira and for the broader NMIBC community," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "MVR-T3011 has demonstrated great therapeutic potential through both direct anti-tumor activity in CIS and immune suppression in papillary (Ta/T1) disease. This represents a synergy of direct oncolysis and immune activation, further enhanced by the integrated effects of exogenous IL-12 and PD-1 antibody expressions within tumor cells. We are committed to rapidly advancing our clinical program to reach broader bladder cancer patient populations and provide meaningful treatment alternatives for those in need.

[1] Due to the small sample size and the early, interim nature of the data, the observed CRR and RFS are subject to statistical uncertainty and are inherently susceptible to change as patient enrollment continues and follow-up matures. These preliminary results should not be construed as an indication of the final outcomes of the current study, nor should they be regarded as predictive of results that may be achieved in a future confirmatory phase III clinical trial or in connection with any regulatory review or approval.

About MVR-T3011

MVR-T3011, represents a breakthrough in HSV-1-based oncolytic immunotherapy. Its proprietary "3-in-1" design unites a replication-competent, tumor-lytic HSV-1 backbone with anti-PD-(L)1 antibody and IL-12, enabling it simultaneously to lyse tumor cells and stimulate innate and adaptive immunity. MVR-T3011 has demonstrated its adaptability and feasibility across multiple routes of administration including intratumoral, intracavitary and intravenous administrations.

(Press release, Immvira, MAY 31, 2026, View Source [SID1234666266])

On May 31, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, reported the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent’s fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and the advancement of business objectives.

ThinkEquity is acting as sole placement agent for the offering.

The securities described above are being offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on January 22, 2024 and declared effective on January 31, 2024. The offering is being made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and can be accessed for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, BriaCell Therapeutics, MAY 31, 2026, View Source [SID1234666282])